AU2008341112B2 - Pre-surgical treatment - Google Patents

Pre-surgical treatment Download PDF

Info

Publication number
AU2008341112B2
AU2008341112B2 AU2008341112A AU2008341112A AU2008341112B2 AU 2008341112 B2 AU2008341112 B2 AU 2008341112B2 AU 2008341112 A AU2008341112 A AU 2008341112A AU 2008341112 A AU2008341112 A AU 2008341112A AU 2008341112 B2 AU2008341112 B2 AU 2008341112B2
Authority
AU
Australia
Prior art keywords
surgical procedure
pharmaceutical composition
brimonidine
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008341112A
Other languages
English (en)
Other versions
AU2008341112A1 (en
Inventor
Jack A. Dejovin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of AU2008341112A1 publication Critical patent/AU2008341112A1/en
Assigned to GALDERMA LABORATORIES, INC. reassignment GALDERMA LABORATORIES, INC. Amend patent request/document other than specification (104) Assignors: GALDERMA LABORATORIES. INC.
Application granted granted Critical
Publication of AU2008341112B2 publication Critical patent/AU2008341112B2/en
Assigned to GALDERMA S.A. reassignment GALDERMA S.A. Request for Assignment Assignors: GALDERMA LABORATORIES, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2008341112A 2007-12-21 2008-12-17 Pre-surgical treatment Ceased AU2008341112B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
US61/015,912 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (2)

Publication Number Publication Date
AU2008341112A1 AU2008341112A1 (en) 2009-07-02
AU2008341112B2 true AU2008341112B2 (en) 2014-02-06

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008341112A Ceased AU2008341112B2 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Country Status (10)

Country Link
US (1) US20110224215A1 (enExample)
EP (1) EP2230910A4 (enExample)
JP (1) JP5580210B2 (enExample)
KR (1) KR20100099191A (enExample)
CN (1) CN101902913B (enExample)
AU (1) AU2008341112B2 (enExample)
BR (1) BRPI0822095A2 (enExample)
CA (1) CA2709199A1 (enExample)
NZ (1) NZ586302A (enExample)
WO (1) WO2009082452A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
WO2010136594A2 (en) 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
SG189896A1 (en) * 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
CA3079824A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. Method for enhancing recovery of cosmetic laser-treated skin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fuchs P N et al: "Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin" *
Hong et al: "Effect of Prophylactic Brimonidine Instillation on Bleeding During Strabismus Srgery in Adults" *
Kratz A et al: "Controlling bleeding from superficial wounds by the use of topical alpha adrenoreceptor agonists spray - A randomized, masked, controlled study" *

Also Published As

Publication number Publication date
CN101902913B (zh) 2014-06-18
AU2008341112A1 (en) 2009-07-02
BRPI0822095A2 (pt) 2014-10-07
US20110224215A1 (en) 2011-09-15
EP2230910A4 (en) 2011-04-13
CA2709199A1 (en) 2009-07-02
NZ586302A (en) 2013-03-28
JP5580210B2 (ja) 2014-08-27
KR20100099191A (ko) 2010-09-10
CN101902913A (zh) 2010-12-01
JP2011507845A (ja) 2011-03-10
EP2230910A1 (en) 2010-09-29
WO2009082452A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AU2008341112B2 (en) Pre-surgical treatment
DK2388007T3 (en) TOPICAL PREPARATION FOR USE IN THE TREATMENT OF rosacea-INDUCED redness
EP2200617A1 (en) Improved brimonidine compositions for treating erythema
CA2761283A1 (en) Combination of adrenergic receptor agonist .alpha.-1 or .alpha.-2, preferably brimonidine with fillers, preferablyhyaluronic acid
US20150313894A1 (en) Combination treatment for rosacea
JP2016525553A (ja) 皮膚肥厚の治療法
AU2012324544B2 (en) Method for treating capillary hemangiomas
US20140329874A1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
CA2850273A1 (en) Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US10039770B2 (en) Prostaglandin F2Alpha and analogues thereof for treating atrophic cutaneous scarring
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GALDERMA S.A.

Free format text: FORMER APPLICANT(S): GALDERMA LABORATORIES, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired